Trials / Completed
CompletedNCT00853450
Bleeding Time Study With AZD6482, Clopidogrel and ASA
A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to evaluate the effect of AZD6482 and clopidogrel on bleeding time when taken together with low-dose ASA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6482 | Single intravenous infusion during a maximum of 5 hours |
| DRUG | Clopidogrel | Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7. |
| DRUG | ASA | 75 mg orally once daily during 7 days in each treatment arm |
Timeline
- Start date
- 2009-02-01
- Completion
- 2009-07-01
- First posted
- 2009-03-02
- Last updated
- 2009-08-19
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00853450. Inclusion in this directory is not an endorsement.